Bliss GVS Pharma announces an acquisition

The Post-Offer Advertisement reported that 1,669 equity shares were validly tendered by public shareholders. At the offer price of Rs 299 per share, the acquirer’s final cash outflow was Rs 4,99,031 (1,669 × Rs 299). ^[1]

The Letter of Offer indicates that, assuming full acceptance of the open offer, the acquirer’s holding would increase to approximately 69.11% of Bliss GVS Pharma’s expanded voting share capital, comprising the 43.11% stake acquired under the Share Purchase Agreement plus the 26.00% open-offer entitlement. The existing promoter group’s holding would fall to 0.00%, as the promoter shares were part of the sale to Anupam Rasayan. ^{[1] [2]}

This change does not result in any immediate reconstitution of the Board of Directors. The Letter of Offer disclosures state that the existing Board would continue initially; any subsequent change in Board composition would be at the acquirer’s discretion and subject to applicable corporate and regulatory requirements. The cited extracts do not indicate an automatic or immediate Board change upon completion of the share acquisition.

Yes—on a full-acceptance basis, the post-offer public shareholding would remain above the 25% MPS threshold, so no further dilution or reclassification would be required solely for MPS compliance.

• The reported promoter holding is 35.010%, implying public shareholding of approximately 64.990% on the same denominator ^[3].
• The open offer is for up to 26.00% of the expanded voting share capital ^[4].
• Derived stress case: 64.990% public holding minus 26.00% accepted in the offer = 38.990% public shareholding. This would leave a buffer of approximately 13.990 percentage points over the 25.00% MPS requirement ^{[3] [4]}.
• The public announcement states that the company must maintain at least 25.00% public shareholding under SEBI LODR and the SCRR; if the transaction caused a shortfall, the acquirer would have to ensure restoration of the required level ^[4].

Accordingly, full acceptance of the offer does not, on the reported numbers, create an MPS shortfall. Any change-of-control or promoter-status reclassification required under the transaction would be a separate regulatory matter, not an MPS-driven dilution requirement.

Caveat: the exact final percentage depends on the actual shares tendered and accepted and the post-offer shareholding pattern. The available announcement specifies the maximum offer size but does not report the final acceptance outcome. Therefore, 38.990% is the conservative full-acceptance calculation, rather than a confirmed final post-offer percentage.